HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MANE

Veradermics, Incorporated (NYSE)

Healthcare — Biotechnology

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Strong Buy 1.2 / 5 5 analysts
$128.48
+$5.54 (+4.51%)
Target: $132.80 (3.4%)
Sign in to add MANE to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$5.37B
P/E Ratio (TTM)-
Forward P/E-42.29
EPS (TTM)$-2.65
Dividend Yield-
Profit Margin-
Revenue Growth-
ROE-
Debt/Equity0.00
Recommendation Strong Buy 1.2
Analyst Target$132.80
Analysts5
Indexes NYSE

Technical Indicators

RSI (14)82.8
Beta-
SMA 20-
SMA 40-
52-Week High$131.24
52-Week Low$32.00
50-Day Avg$101.09
200-Day Avg$77.49
Avg Volume657.9K
Volume530.8K

Performance Analysis

NEUTRAL

MANE presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($131.24), which may indicate limited upside.
- RSI at 82.8 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Wall Street consensus is "Strong Buy" from 5 analysts.
+ Average analyst target of $132.80 implies 3.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:19 UTC

Back to Screener Export Report